Correlation Between Aldeyra and Corvus Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Aldeyra and Corvus Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aldeyra and Corvus Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Aldeyra and Corvus Pharmaceuticals, you can compare the effects of market volatilities on Aldeyra and Corvus Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aldeyra with a short position of Corvus Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aldeyra and Corvus Pharmaceuticals.

Diversification Opportunities for Aldeyra and Corvus Pharmaceuticals

-0.6

Correlation Coefficient

Aldeyra  Corvus Pharmaceuticals

Excellent diversification

The 3 months correlation between Aldeyra and Corvus is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding Aldeyra and Corvus Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Corvus Pharmaceuticals and Aldeyra is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aldeyra are associated (or correlated) with Corvus Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Corvus Pharmaceuticals has no effect on the direction of Aldeyra i.e., Aldeyra and Corvus Pharmaceuticals go up and down completely randomly.

Pair Corralation between Aldeyra and Corvus Pharmaceuticals

Given the investment horizon of 90 days Aldeyra is expected to under-perform the Corvus Pharmaceuticals. In addition to that, Aldeyra is 1.16 times more volatile than Corvus Pharmaceuticals. It trades about -0.06 of its total potential returns per unit of risk. Corvus Pharmaceuticals is currently generating about 0.08 per unit of volatility. If you would invest  889.00  in Corvus Pharmaceuticals on August 30, 2024 and sell it today you would earn a total of  53.00  from holding Corvus Pharmaceuticals or generate 5.96% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Aldeyra  vs.  Corvus Pharmaceuticals

Aldeyra

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Aldeyra has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest uncertain performance, the Stock's fundamental indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Corvus Pharmaceuticals

Risk-Adjusted Performance

20 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Corvus Pharmaceuticals are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Corvus Pharmaceuticals unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Aldeyra and Corvus Pharmaceuticals

The main advantage of trading using opposite Aldeyra and Corvus Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aldeyra position performs unexpectedly, Corvus Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corvus Pharmaceuticals will offset losses from the drop in Corvus Pharmaceuticals' long position.

The idea behind Aldeyra and Corvus Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.